PF03491390
| CAS No. | 254750-02-2 | Cat. No. | BCP07463 |
| Name | PF03491390 | ||
| Synonyms | Emricasan;IDN6556;IDN 6556;IDN-6556;PF-03491390;PF 03491390; | ||
| Formula | C26H27F4N3O7 | M. Wt | 569.5 |
| Description | Emricasan, also known as IDN 6556 and PF 03491390, is a first-in-class caspase inhibitor in clinical trials for the treatment of liver diseases. Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis. IDN6556 facilitates marginal mass islet engraftment in a porcine islet autotransplant model. Oral IDN-6556 may lower aminotransferase activity in patients with chronic hepatitis C. Orally-administered PF-03491390 is retained in the liver for prolonged periods with low systemic exposure, exerting a hepatoprotective effect against alpha-fas-induced liver injury in a mouse model. | ||
| Pathways | Protease/Metabolic Enzyme Apoptosis Pathway | ||
| Targets | Caspase | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.